Spark Therapeutics (ONCE) Earns “Buy” Rating from Stifel Nicolaus
Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “buy” rating reiterated by stock analysts at Stifel Nicolaus in a report released on Wednesday, MarketBeat reports. They presently have a $64.00 price target on the biotechnology company’s stock, down from their previous price target of $73.00. Stifel Nicolaus’ price objective would suggest a potential upside of 27.06% from the stock’s previous close.
A number of other brokerages have also recently issued reports on ONCE. Royal Bank of Canada reiterated a “buy” rating on shares of Spark Therapeutics in a report on Wednesday, October 25th. Cantor Fitzgerald set a $100.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. cut Spark Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $62.00 to $60.00 in a report on Wednesday, February 14th. UBS Group cut Spark Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $92.00 to $51.00 in a report on Tuesday, December 12th. Finally, Leerink Swann cut Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 target price on the stock. in a report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $69.98.
Spark Therapeutics (ONCE) opened at $50.37 on Wednesday. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $91.75. The stock has a market capitalization of $2,016.80, a price-to-earnings ratio of -6.98 and a beta of 3.02.
In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the transaction, the insider now directly owns 215,000 shares in the company, valued at approximately $15,333,800. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.30% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after purchasing an additional 241,016 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Spark Therapeutics by 6.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock valued at $18,489,000 after purchasing an additional 11,785 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Spark Therapeutics during the 3rd quarter valued at $5,286,000. Alyeska Investment Group L.P. purchased a new stake in shares of Spark Therapeutics during the 3rd quarter valued at $13,519,000. Finally, Principal Financial Group Inc. increased its position in shares of Spark Therapeutics by 23.8% during the 3rd quarter. Principal Financial Group Inc. now owns 54,088 shares of the biotechnology company’s stock valued at $4,822,000 after purchasing an additional 10,399 shares during the last quarter.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.